Axis-Shield and Abbott are to cement their relationship in the field of in vitro diagnostics by developing and commercialising a new HbA1c immunoassay. Under the terms of the deal, Axis-Shield will develop the immunoassay to run on Abbott’s Architect high-throughput analyser ...
Please Login to read the full article.
